Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming

Abstract

Fusogenic membrane glycoproteins (FMG) are a family of viral genes that, when expressed in tumour cells, trigger extensive cell to cell fusion and subsequent cell death. Gene therapy approaches using FMG are also potentially immunogenic, since syncitia generated ex vivo can be therapeutic as antitumour vaccines in murine models. This study has addressed the mechanisms responsible for the immunogenicity of FMG-mediated cell death, and its applicability to human immune priming. We show that fusion of human Mel888 melanoma cells following transfection with FMG can reverse the suppressive effects of Mel888 on dendritic cells (DC) phenotype, and potentiate IL-12 production by DC on activation in a cell contact-dependent manner. DC loaded with fusing, but not intact, tumour cells primed a naive, tumour-specific cytotoxic T-cell response, which was MHC class I-restricted and associated with production of high levels of IFNγ and, later, IL-5. Fusing cells were an effective source of antigen for DC cross-priming and presentation of the melanoma-specific antigen gp100 to a specific T-cell clone. These data show, in a human system, that FMG represent an immunogenic, as well as cytotoxic, gene therapy for cancer, reversing the inhibitory effects of tumour cells on DC to potentiate IL-12 production and naive T-cell priming.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Bateman A, Bullough F, Murphy S, Emiliusen L, Lavillette D, Cosset FL et al. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res 2000; 60: 1492–1497.

    CAS  PubMed  Google Scholar 

  2. Diaz RM, Bateman A, Emiliusen L, Fielding A, Trono D, Russell SJ et al. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Gene Therapy 2000; 7: 1656–1663.

    Article  CAS  Google Scholar 

  3. Bateman AR, Harrington KJ, Kottke T, Ahmed A, Melcher AA, Gough MJ et al. Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Res 2002; 62: 6566–6578.

    CAS  PubMed  Google Scholar 

  4. Higuchi H, Bronk SF, Bateman A, Harrington K, Vile RG, Gores GJ . Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy. Cancer Res 2000; 60: 6396–6402.

    CAS  PubMed  Google Scholar 

  5. Srivastava P . Roles of heat–shock proteins in innate and adaptive immunity. Nat Rev Immunol 2002; 2: 185–194.

    Article  CAS  Google Scholar 

  6. Linardakis E, Bateman A, Phan V, Ahmed A, Gough M, Olivier K et al. Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell–tumor cell fusion. Cancer Res 2002; 62: 5495–5504.

    CAS  PubMed  Google Scholar 

  7. Melief CJ . Mini-review: regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur J Immunol 2003; 33: 2645–2654.

    Article  CAS  Google Scholar 

  8. De Smedt T, Van Mechelen M, De Becker G, Urbain J, Leo O, Moser M . Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol 1997; 27: 1229–1235.

    Article  CAS  Google Scholar 

  9. Steinman RM, Hawiger D, Nussenzweig MC . Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685–711.

    Article  CAS  Google Scholar 

  10. Valenzuela J, Schmidt C, Mescher M . The roles of IL-12 in providing a third signal for clonal expansion of naive CD8T cells. J Immunol 2002; 169: 6842–6849.

    Article  CAS  Google Scholar 

  11. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F . Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 2000; 1: 311–316.

    Article  CAS  Google Scholar 

  12. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S et al. Production of vascular endothelial growth factor by human tumours inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096–1103.

    Article  CAS  Google Scholar 

  13. Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998; 92: 4778–4791.

    CAS  PubMed  Google Scholar 

  14. Shurin GV, Shurin MR, Bykovskaia S, Shogan J, Lotze MT, Barksdale Jr EM . Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 2001; 61: 363–369.

    CAS  PubMed  Google Scholar 

  15. Shurin MR, Yurkovetsky ZR, Tourkova IL, Balkir L, Shurin GV . Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10. Int J Cancer 2002; 101: 61–68.

    Article  CAS  Google Scholar 

  16. Kiertscher SM, Luo J, Dubinett SM, Roth MD . Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 2000; 164: 1269–1276.

    Article  CAS  Google Scholar 

  17. Trinchieri G . Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133–146.

    Article  CAS  Google Scholar 

  18. Melero I, Duarte M, Ruiz J, Sangro B, Galofre J, Mazzolini G et al. Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Therapy 1999; 6: 1779–1784.

    Article  CAS  Google Scholar 

  19. Rodriguez-Calvillo M, Duarte M, Tirapu I, Berraondo P, Mazzolini G, Qian C et al. Upregulation of natural killer cells functions underlies the efficacy of intratumorally injected dendritic cells engineered to produce interleukin-12. Exp Hematol 2002; 30: 195–204.

    Article  CAS  Google Scholar 

  20. Miller G, Lahrs S, Dematteo RP . Overexpression of interleukin-12 enables dendritic cells to activate NK cells and confer systemic antitumor immunity. FASEB J 2003; 17: 728–730.

    Article  CAS  Google Scholar 

  21. Kuppner MC, Gastpar R, Gelwer S, Nossner E, Ochmann O, Scharner A et al. The role of heat shock protein (hsp70) in dendritic cell maturation: hsp70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors. Eur J Immunol 2001; 31: 1602–1609.

    Article  CAS  Google Scholar 

  22. Bethke K, Staib F, Distler M, Schmitt U, Jonuleit H, Enk AH et al. Different efficiency of heat shock proteins (HSP) to activate human monocytes and dendritic cells: superiority of HSP60. J Immunol 2002; 169: 6141–6148.

    Article  CAS  Google Scholar 

  23. Noessner E, Gastpar R, Milani V, Brandl A, Hutzler PJ, Kuppner MC et al. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunol 2002; 169: 5424–5432.

    Article  CAS  Google Scholar 

  24. Akira S, Takeda K, Kaisho T . Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2: 675–680.

    Article  CAS  Google Scholar 

  25. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000; 1: 398–401.

    Article  CAS  Google Scholar 

  26. Takatsu K, Kikuchi Y, Takahashi T, Honjo T, Matsumoto M, Harada N et al. Interleukin 5, a T-cell-derived B-cell differentiation factor also induces cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1987; 84: 4234–4238.

    Article  CAS  Google Scholar 

  27. Ramos T . Interleukin 5 is a differentiation factor for cytotoxic T lymphocytes. Immunol Lett 1989; 21: 277–283.

    Article  CAS  Google Scholar 

  28. Apostolopoulos V, McKenzie IF, Lees C, Matthaei KI, Young IG . A role for IL-5 in the induction of cytotoxic T lymphocytes in vivo. Eur J Immunol 2000; 30: 1733–1739.

    Article  CAS  Google Scholar 

  29. Gong J, Chen D, Kashiwaba M, Kufe D . Induction of antitumour activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997; 3: 558–561.

    Article  CAS  Google Scholar 

  30. Gong J, Avigan D, Chen D, Wu Z, Koido S, Kashiwaba M et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 2000; 97: 2715–2718.

    Article  CAS  Google Scholar 

  31. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000; 6: 332–336.

    Article  CAS  Google Scholar 

  32. Hayashi T, Tanaka H, Tanaka J, Wang R, Averbook BJ, Cohen PA et al. Immunogenicity and therapeutic efficacy of dendritic–tumor hybrid cells generated by electrofusion. Clin Immunol 2002; 104: 14–20.

    Article  CAS  Google Scholar 

  33. Phan V, Errington F, Cheong SC, Kottke T, Gough M, Altmann S et al. A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell–tumor cell hybrid vaccines. Nat Med 2003; 9: 1215–1219.

    Article  CAS  Google Scholar 

  34. Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996; 196: 137–151.

    Article  CAS  Google Scholar 

  35. Sallusto F, Lanzavecchia A . Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumour necrosis factor alpha. J Exp Med 1994; 179: 1109–1118.

    Article  CAS  Google Scholar 

  36. Fielding AK, Chapel-Fernandes S, Chadwick MP, Bullough FJ, Cosset FL, Russell SJ . A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display. Hum Gene Ther 2000; 11: 817–826.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A Melcher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Errington, F., Jones, J., Merrick, A. et al. Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming. Gene Ther 13, 138–149 (2006). https://doi.org/10.1038/sj.gt.3302609

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302609

Keywords

This article is cited by

Search

Quick links